Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Erythromycin plus nasogastric tube lavage vs metoclopramide plus nasogastric tube lavage Blood transfusion · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Erythromycin vs placebo All‐cause mortality · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | RD 0 | 3 studies · 255 participants | Very low |
Erythromycin vs placebo Visualisation of gastric mucosa · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | 2 studies · 195 participants | Low |
Erythromycin vs placebo NSAEs · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | RD 0.01 | 3 studies · 255 participants | Very low |
Erythromycin vs placebo Rebleeding · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | RR 0.63 [0.13, 2.9] | 2 studies · 195 participants | Very low |
Erythromycin vs placebo Blood transfusion · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | 3 studies · 255 participants | Low |
Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage UGIH‐related mortality · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | 1 study · 29 participants | Very low |
Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage SAEs · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | 6 studies · 408 participants | Very low |
STW5 (Iberogast) vs placebo Global symptoms of dyspepsia · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | no estimate extracted | 5 studies · 814 participants | Very low |
Curcuma longa vs placebo Global symptoms of dyspepsia (responders) · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | RR 1.5 [1.06, 2.11] | 1 study · 76 participants | Low |
Curcuma longa vs placebo Adverse events Assessed clinically · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | RR 1.26 [0.51, 3.08] | 1 study · 89 participants | Moderate |
Curcuma longa vs placebo Quality of life · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | no estimate extracted | 1 study · 89 participants | Moderate |
STW5 (Iberogast) vs placebo Global symptoms of dyspepsia (responders) · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | RR 1.55 [0.98, 2.47] | 2 studies · 324 participants | Low |
STW5 (Iberogast) vs placebo Adverse events Assessed clinically · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | RR 0.92 [0.52, 1.64] | 4 studies · 786 participants | Low |
STW5 (Iberogast) vs placebo Quality of life · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | no estimate extracted | 1 study · 52 participants | Low |
Peppermint/caraway oil vs placebo Global symptoms of dyspepsia · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | no estimate extracted | 2 studies · 210 participants | Moderate |
Peppermint/caraway oil vs placebo Global symptoms of dyspepsia (responders) · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | RR 1.53 [1.3, 1.81] | 3 studies · 305 participants | Moderate |
Peppermint/caraway oil vs placebo Adverse events Assessed clinically · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | RR 1.56 [0.69, 3.53] | 3 studies · 305 participants | Low |
Peppermint/caraway oil vs placebo Quality of life · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | no estimate extracted | 1 study · 99 participants | Moderate |
Curcuma longa vs placebo Global symptoms of dyspepsia · participants with functional dyspepsia Non‐Chinese herbal medicines for functional dyspepsia (2023) · Cochrane | no estimate extracted | 2 studies · 110 participants | Moderate |
Vedolizumab vs placebo Induction of clinical remission (6–10 weeks) · children or adults with Crohn's disease Vedolizumab for induction and maintenance of remission in Crohn's disease (2023) · Cochrane | RR 1.61 [1.2, 2.17] | 4 studies · 1126 participants | High |
Vedolizumab vs placebo Induction of clinical response (6–10 weeks) · children or adults with Crohn's disease Vedolizumab for induction and maintenance of remission in Crohn's disease (2023) · Cochrane | RR 1.43 [1.19, 1.71] | 4 studies · 1126 participants | High |
Vedolizumab vs placebo Adverse events (6–10 weeks) · children or adults with Crohn's disease Vedolizumab for induction and maintenance of remission in Crohn's disease (2023) · Cochrane | RR 1.01 [0.93, 1.11] | 4 studies · 1126 participants | Moderate |
Vedolizumab vs placebo Serious adverse events (6–10 weeks) · children or adults with Crohn's disease Vedolizumab for induction and maintenance of remission in Crohn's disease (2023) · Cochrane | RR 0.91 [0.62, 1.33] | 4 studies · 1126 participants | Low |
Vedolizumab vs placebo Maintenance of clinical remission (52–60 weeks) · children or adults with Crohn's disease Vedolizumab for induction and maintenance of remission in Crohn's disease (2023) · Cochrane | RR 1.52 [1.24, 1.87] | 3 studies · 894 participants | High |
Vedolizumab vs placebo Adverse events (52–60 weeks) · children or adults with Crohn's disease Vedolizumab for induction and maintenance of remission in Crohn's disease (2023) · Cochrane | RR 1 [0.94, 1.07] | 3 studies · 894 participants | Moderate |
Vedolizumab vs placebo Serious adverse events (52–60 weeks) · children or adults with Crohn's disease Vedolizumab for induction and maintenance of remission in Crohn's disease (2023) · Cochrane | RR 0.98 [0.68, 1.39] | 3 studies · 894 participants | Low |
Patient education and standard care vs standard care Disease activity (3‐12 months) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 2 studies · 479 participants | Moderate |
Weekly educational texts messages vs once every other week educational text messages Flare‐ups or relapse (continuous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Weekly educational texts messages vs once every other week educational text messages Flare‐ups or relapse (dichotomous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Weekly educational texts messages vs once every other week educational text messages Quality of life, IBDQ (32 minimum score ‐ 224 maximum score; high score = better quality of life) (12 months) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 1 study · 193 participants | Very low |
Patient education and standard care vs standard care Flare‐ups or relapse (mean number during study period, start‐12 months) (continuous outcome) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 2 studies · 1022 participants | Moderate |
Patient education and standard care vs standard care Flare‐ups or relapse (4‐12 months) (dichotomous outcome) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | RR 0.94 [0.41, 2.18] | 3 studies · 307 participants | Very low |
Patient education and standard care vs standard care Quality of life (2 weeks‐12 months) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 6 studies · 1364 participants | Moderate |
Web‐based patient education vs other delivery of patient education Disease activity (8 weeks) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 1 study · 32 participants | Very low |
Web‐based patient education vs other delivery of patient education Flare‐ups or relapse (continuous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based patient education vs other delivery of patient education Flare‐ups or relapse (dichotomous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based patient education vs other delivery of patient education Quality of life, IBDQ (32 minimum score to 224 maximum score; high score = better quality of life) (8 weeks) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 1 study · 58 participants | Very low |
Weekly educational texts messages vs once every other week educational text messages Disease activity (12 months) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 1 study · 131 participants | Very low |
Summary of findings table ‐ Fecal microbiota transplantation (FMT) vs control Resolution of rCDI · adults with recurrent Clostridioides difficile infection (rCDI) Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium… (2023) · Cochrane | RR 1.92 [1.36, 2.71] | 6 studies · 320 participants | Moderate |
Summary of findings table ‐ Fecal microbiota transplantation (FMT) vs control Serious adverse events · adults with recurrent Clostridioides difficile infection (rCDI) Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium… (2023) · Cochrane | RR 0.73 [0.38, 1.41] | 6 studies · 320 participants | Moderate |
Summary of findings table ‐ Fecal microbiota transplantation (FMT) vs control All‐cause mortality · adults with recurrent Clostridioides difficile infection (rCDI) Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium… (2023) · Cochrane | RR 0.57 [0.22, 1.45] | 6 studies · 320 participants | Low |
Summary of findings table ‐ Fecal microbiota transplantation (FMT) vs control Colectomy · adults with recurrent Clostridioides difficile infection (rCDI) Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium… (2023) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Web‐based disease monitoring vs usual care Disease activity (adults) · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 3 studies · 428 participants | Moderate |
Web‐based disease monitoring vs self‐screening Flare‐ups/relapse (dichotomous; adults) · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 1 study · 102 participants | Very low |
Web‐based disease monitoring vs self‐screening Quality of life (adults) · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 1 study · 102 participants | Very low |
Telephone‐based disease monitoring vs face‐to‐face monitoring Disease activity (adults) · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
Telephone‐based disease monitoring vs face‐to‐face monitoring Flare‐ups/relapse (dichotomous; adults) · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | RR 1.17 [0.47, 2.89] | 1 study · 42 participants | Very low |
Telephone‐based disease monitoring vs face‐to‐face monitoring Flare‐ups/relapse (dichotomous; children) · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | RR 0.24 [0.03, 2.05] | 1 study · 86 participants | Very low |
Telephone‐based disease monitoring vs face‐to‐face monitoring Quality of life (adults) · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | 2 studies · 123 participants | Very low |